Isovaleric acidemia: medical and neurodevelopmental effects of long-term therapy.
Nine patients with isovaleric acidemia were treated with a low-protein diet and supplemental glycine for up to 10 years. Carnitine was added to the therapy in four patients. Overall, the treatment was well tolerated, resulting in no significant side effects other than persistent hyperglycinemia. Normal growth was observed in all patients. Of four patients with the chronic phenotype, three, whose treatment was delayed beyond the first year of life, are mentally retarded. Two of five patients with the acute phenotype are retarded. The outcome in these two was complicated in one by neonatal intraventricular hemorrhage and in the other by therapeutic noncompliance. In our patients, only those who were treated successfully from early infancy and had no complications did not develop mental retardation. After initiation of therapy, there was a significant decrease in ketoacidotic attacks requiring hospitalization. Glycine is indicated for the treatment of acute ketoacidosis in these patients; none of the catastrophically ill newborn who received glycine died. The aim of treatment is to reduce the isovaleric acid burden to a minimum. Therapy consisting of leucine restriction with supplemental glycine and carniline should be started as soon as possible after birth.
Berry
G T
GT
Department of Pediatrics and Medicine, University of Pennsylvania School of Medicine, Philadelphia.
Yudkoff
M
M
Segal
S
S
D000592:Amino Acid Metabolism, Inborn Errors / Q000178:diet therapy* / Q000188:drug therapy / Q000503:physiopathology; D002331:Carnitine / Q000008:administration & dosage; D002657:Child Development; D004044:Dietary Proteins / Q000008:administration & dosage; D005260:Female; D005998:Glycine / Q000008:administration & dosage; D006128:Growth; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007360:Intelligence; D050769:Isovaleryl-CoA Dehydrogenase; D008297:Male; D010088:Oxidoreductases / Q000172:deficiency*; D044925:Oxidoreductases Acting on CH-CH Group Donors
D004044:Dietary Proteins; D010088:Oxidoreductases; D044925:Oxidoreductases Acting on CH-CH Group Donors; D050769:Isovaleryl-CoA Dehydrogenase; D002331:Carnitine; D005998:Glycine